Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Lilly

Vanderbilt Will Build an AI Agent into Medical Records to Cut the Wait for Alzheimer's Infusions

Vanderbilt will build an AI triage agent into its EHR to speed Alzheimer's patients to treatment. What it would do, and who is funding it.

Medical Daily

Eczema Patients on Ebglyss Can Stretch Maintenance Shots to Every Eight Weeks, but Only After a Full Induction Course

FDA approved every-eight-week Ebglyss maintenance dosing for atopic dermatitis. Who qualifies, what maintenance dosing means, and what to ask.

Medical Daily

FDA Grants Breakthrough Therapy Status to a Pancreatic Cancer Drug for a Mutation Found in Roughly 1 in 50 Patients

FDA gave olomorasib breakthrough therapy status for KRAS G12C pancreatic cancer. What the designation means, who it applies to, and what it does not prove.

Medical Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Retatrutide Will Not Reach the FDA Until Early 2027, Leaving No Price and No Coverage Decision to Point To

Lilly will not file retatrutide with the FDA until early 2027. What that delay means for cost, insurance coverage, and patients considering waiting.

Medical Daily

Lilly Files Its GLP-1 Pill for Diabetes, and the Manufacturing Case Is Stronger Than the Access Case

Lilly submitted its oral GLP-1 for type 2 diabetes. Why pills are easier to manufacture than injectables, and why coverage still decides access.

Medical Daily

Lilly Says Weight Loss Drug Prices Fell 13 Percent Worldwide, but the US Decline Was Far Smaller

Lilly reported a 13% drop in realized prices, but US prices fell only 3%. Here is what that means for Zepbound patients and out-of-pocket costs.

Medical Daily

Eli Lilly Stock: Analyst Estimates & Ratings

Eli Lilly's market-beating performance has done little to temper Wall Street's optimism, with analysts continuing to see meaningful upside in the stock.

Barchart

Read news from The Economist, FT, and more,
with one subscription

Adding a Muscle Targeting Antibody to Semaglutide Cut Lean Mass Loss from 7.4% to 2.9% in a Phase 2 Trial

A 507-person trial found bimagrumab plus semaglutide protected lean mass while increasing fat loss. The drug remains investigational.

Medical Daily

Bank of America CEO Says The Company Spends $250 Million A Year on GLP-1 Drugs for Their Employees. He Calls It a Good Investment

Bank of America CEO Brian Moynihan said the company has dramatically increased its investment in medications such as Novo Nordisk's Ozempic and Wegovy and Eli Lilly's Zepbound.

International Business Times

LLY Stock Alert: What to Know as Eli Lilly Teams Up With CVS on Weight-Loss Drugs

Eli Lilly shares rally on a fresh DTC partnership with CVS Health. A strong Q2 release and impressive future guidance is driving LLY stock higher as well.

Barchart

Eli Lilly's Weight-Loss Empire Keeps Expanding As Mounjaro, Zepbound Generate Nearly $15 Billion

Eli Lilly and Co. (NYSE:LLY) stock traded higher Wednesday after the drugmaker reported second-quarter results that topped Wall Street expectations and raised its full-year revenue outlook, driven by continued demand for its diabetes and obesity treatments.

Benzinga

Eli Lilly Raises Sales Forecast As Weight Loss Drug Demand Soars. Its Stock is Climbing

Eli Lilly posted stronger-than-expected second-quarter earnings and revenue, boosted by surging demand for Zepbound and Mounjaro, while its newly launched obesity pill Foundayo made its first contribution to quarterly sales.

International Business Times

A Next-Generation Obesity Drug Has Been Released By Eli Lilly in Early Access to Select Patients

Eli Lilly will offer early access to the investigational obesity drug retatrutide after positive Phase 3 trials showed significant weight-loss results.

Medical Daily

Michigan Supreme Court Clears the Way for a State Investigation into Eli Lilly Insulin Pricing

Michigan's high court ruled 4-3 that the state may investigate Eli Lilly's insulin pricing. The decision authorizes a probe, not a finding of wrongdoing.

Medical Daily

Get all your
news in one place.

100's of premium titles.
One news app.

Medical Daily

Daily Oral Weight Loss Pill Outperformed Oral Semaglutide On Weight And Blood Sugar In Type 2 Diabetes

In a 1,698-person trial, orforglipron beat oral semaglutide on A1C and weight in type 2 diabetes. Here is what was measured and what was not.

Livingetc

5 Small Garden Before and After Makeovers That Will Help You See the Potential in Your Own Tiny Space

These tiny garden transformations prove you don't need a lot of space to make a big impact

The Economic Times

Novo Nordisk pursues preliminary injunction to block Eli Lilly weight-loss drug ads

Novo Nordisk is seeking a court injunction to stop Eli Lilly's drug advertisements. The Danish company claims Lilly's ads mislead consumers about treatment comparisons. Lilly denies wrongdoing and stands by its advertising claims. Both companies compete in the growing obesity and diabetes drug market. Novo Nordisk argues Lilly uses outdated…

International Business Times

Eli Lilly Cleared Two More Trials For Its Next-Generation Obesity Drug. It Will Seek FDA Approval Next Year

After 80 weeks of treatment, obese, non-diabetic participants receiving retatrutide lost an average of 22.6% of their body weight while also showing improvements in several cardiometabolic risk factors.

Get all your
news in one place.

100's of premium titles.
One news app.

Medical Daily

The First Oral GLP-1 Weight Loss Pill With No Food or Injection Requirements Is Now Available

Eli Lilly's Foundayo (orforglipron) is the first oral GLP-1 obesity pill with no food or water restrictions. FDA approved it April 1, 2026. Here is what patients should know.

Barchart

What You Need to Know Ahead of Eli Lilly's Earnings Release

Eli Lilly will release its second-quarter earnings next month, and analysts anticipate a double-digit bottom-line growth.

The Independent UK

Two weight-loss drugmakers in legal battle over which is most effective in helping users shed pounds

Novo Nordisk claims Eli Lilly compared peak doses of Zepbound against outdated, lower doses of Wegovy to advertise a 50-pound weight loss versus 33 pounds

International Business Times

Novo Nordisk Says Eli Lilly Used Misleading Weight Loss Drug Advertising. It's Suing

The lawsuit, filed Tuesday, alleges that Eli Lilly violated federal and state false advertising laws by promoting "knowingly outdated clinical trial" results that compare both companies' drugs.

The Economic Times

Novo Nordisk sues Eli Lilly, accusing it of false advertising of weight-loss drug

Novo Nordisk has sued Eli Lilly in a U.S. court. The Danish company accuses Lilly of false advertising for its weight-loss medicines. Novo claims Lilly compared lower doses of its drugs with higher doses of Lilly's. Lilly's advertisements allegedly omit newer, higher-dose versions of Novo's medicines. Novo seeks to withdraw…

Kiplinger

Nasdaq Sinks as Chip Stocks Drop Again: Stock Market Today

While Taiwan Semi's post-earnings drop pressured chipmakers, healthcare names outperformed thanks to Merck's FDA win and Eli Lilly's big buy.

International Business Times

Eli Lilly Changed Depression Care With Prozac. Now It's Betting on Psychedelics with AtaiBeckley Acquisition

Eli Lilly is making its biggest move yet into the rapidly evolving field of psychedelic medicine, acquiring clinical-stage biotechnology company AtaiBeckley in a deal valued at up to $3.8 billion.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Eli Lilly and Company

61 stories

STAT

44 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.